32.5mg Pre-Filled Research Pen – Ready-to-use laboratory presentation designed for research applications.

Triple Receptor Agonist – Investigated for activity at the GLP-1, GIP, and glucagon receptors.

Advanced Metabolic Research Compound – A focus of ongoing scientific research into metabolism and energy regulation.

Precision Pen Format – Pre-filled design for consistent handling in controlled research settings.

High-Purity Research Peptide – Manufactured to support laboratory and preclinical investigation.

Convenient Presentation – Eliminates the need for peptide reconstitution before laboratory use.

Individual Protective Packaging – Securely packaged to help maintain product integrity during storage and transport.

Research-Focused Design – Suitable for metabolic, obesity, glucose regulation, and energy balance research.

Quality Manufactured – Produced under established manufacturing processes with batch consistency in mind.

Cold Chain Compatible – Designed for refrigerated storage to support product stability according to manufacturer recommendations.

Retatrutide (LY3437943) has been evaluated in multiple clinical trials investigating obesity and metabolic disease. Trial protocols generally used once-weekly administration with gradual dose escalation over several weeks to improve tolerability before reaching target maintenance doses. Different studies evaluated multiple maintenance-dose arms depending on the study design, rather than a single fixed regimen.

Researchers are investigating Retatrutide because it acts as a triple agonist targeting:

• 
  GLP-1 receptors
  
• 
  GIP receptors
  
• 
  Glucagon receptors
  

Current research focuses on:

• 
  Body weight regulation
  
• 
  Energy expenditure
  
• 
  Glucose metabolism
  
• 
  Cardiometabolic health
  
• 
  Appetite signalling
  

Retatrutide remains under clinical investigation, with Phase 3 studies ongoing and regulatory submissions planned; it is not yet approved for routine prescribing.

Frequently Asked Questions

What is Retatrutide?

Retatrutide is an investigational triple receptor agonist currently being studied for its effects on metabolism and weight regulation.

Why is it called a triple agonist?

Because it activates the GLP-1, GIP and glucagon receptors simultaneously.

What makes it different from GLP-1 compounds?

Unlike traditional GLP-1 receptor agonists, Retatrutide also activates GIP and glucagon receptors, creating a broader metabolic response under investigation.

Is this supplied as a vial?

No. This product is supplied as a pre-filled research pen.

What type of studies use Retatrutide?

Researchers investigate Retatrutide in studies relating to obesity, metabolism, insulin sensitivity and energy expenditure.

Is Retatrutide FDA approved?

Retatrutide remains an investigational compound and continues to be evaluated through clinical research.

Why is the pen format beneficial?

The pre-filled format provides a consistent presentation for laboratory research and handling.

How should the product be stored?

Store refrigerated according to the manufacturer's recommendations. Avoid excessive heat, freezing (unless specified by the manufacturer), and prolonged exposure to direct sunlight.

Is this suitable for laboratory research?

Yes, it is intended for laboratory and scientific research applications.

What receptor pathways are being investigated?

Researchers are studying GLP-1, GIP and glucagon receptor activation and their combined influence on metabolic processes.

Compound: Retatrutide

Presentation: 32.5mg Pre-filled Research Pen

Research Category:

Triple-Incretin Receptor Agonist

Research Areas Include:

• 
  Obesity research
  
• 
  Metabolic disease models
  
• 
  Glucose regulation studies
  
• 
  Appetite signalling
  
• 
  Energy balance
  
• 
  Weight management research
  
• 
  Insulin sensitivity investigations